anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A pharmaceutical liposomal formulation for photodynamic therapy comprising a non-polar porphyrin photosensitizer and one or more phospholipids, which are stable in storage without requiring freeze- drying is described. The liposomal formulation provides therapeutically effective amounts of the photosensitizer for intravenous administration. The phospholipids may be modified by pegylation, i.e. they contain poly ethylene glycol as an integral part of the phospholipids. The formed liposomes contain the non-polar photosensitizer within the membrane and are useful for the combined targeting of a nonpolar photosensitizer and a second polar substance. When a formulation includes the presence of monosaccharides or polyalcohols, it can be efficiently freeze-dried preserving the size of the liposomal vehicles and the content of a therapeutically effective amount of the photosensitizing agent. The invention also relates to the liposome composition formed upon reconstitution with an aqueous vehicle. The freeze-dried formulation upon reconstitution with a suitable aqueous vehicle forms liposomes that are also useful for intravenous administration.
The invention describes a non-staining composition comprising high content of curcuminoids in granular form, which is substantially free of excipients and is comprised of at least about 94% of curcuminoids. The non-staining composition may be comprised of 0 to 5% by weight of excipients, which are used as processing aids. The non-staining curcuminoid composition does not cause staining and dusting of the equipment and the contact surfaces, while formulating into finished dosage forms. The invention also relates to solvent-free process for preparation of non-staining granular composition; wherein the curcuminoids may be subjected to granulation process at specific temperature conditions. The granular composition is free flowing and retains original yellowish orange colour of the curcuminoids along with its crystalline nature. The solvent-free process for non-staining granular curcuminoid composition is simple, economical and environment friendly, thus making it industrially useful and applicable for formulating finished dosage forms.
A system for encoding and encompassing healthcare provider billing, more particularly, a computer assisted network for encoding, documenting and processing claims for payment of specific procedures by alternative therapy providers, grouped geographically and by specialty. The system employs a computer accessing three main databases for identifying, encoding and calculation of average costs of provider services. A resulting Alternative Billing Code (ABC) is produced which can be compared and correlated with insurance industry standard codes. The ABC has the attribute of conveying multiple levels of information through alphanumeric characters. The ABC is an assembly of a series of terms and sub-terms from databases, namely Alternative Practice Type (APT), Standard Alternative Procedure Descriptions (SAPDs), Provider Data (PD) and RVU (Relative Value Unit) databases. Each provider specialty includes its own listing of treatments which are turned into RVUs, thus establishing a sequence of treatment fees and charges. The APT code and SAPD code are stored in a PD file including average claims costs of all providers as categorized by a predetermined grouping, which with the PD create the ABC as a comprehensive, single code representing all elements of treatment incident to a patient visit. Claims for payment are submitted and translated into an appropriate code for determination of payment under the present system.
All persons admitted to the inpatient rehabilitation unit will be screened for inclusion. Only those with a confirmed diagnosis of stroke (CVA) will be included. Data collection on the participants will begin at the time of admission and continue through discharge. Average length of stay for persons with stroke in inpatient rehabilitation units is 21 days. Some persons will stay fewer days and some will stay longer. Data collection will include key information on physical therapy interventions including gait training, balance training, group therapy, manual therapy, exercise, transfer training, stairs, family training, wheelchair training, modalities, discharge planning, seated and supine exercises. Other data will be collected including tone, motor control, sensation, gait endurance, falls, wounds, restraints, deep vein thrombosis, tracheostomy, feeding tubes and blood pressure. Additional data collection will include age, gender, race, length of time post stroke, time in rehabilitation, Functional Independence Measure scores, case mix group, discharge destination. In addition, physician history and physical as well as discharge summary will be collected, as will evaluation and discharge notes from therapies (physical, occupation, speech, social work). Patients will not be responsible for any costs associated with this data collection.
Prostaglandin compounds of the formulae <IMAGE>  and <IMAGE> in which the substituents are defined in Claim 1, are prepared. These compounds are obtained by starting from a compound of the formula <IMAGE> and reducing the 9-oxo group in this to the hydroxyl group and subsequently acylating. The silyl protective group is then eliminated, and the radical -CH2-COOR11 is introduced into the side chain by condensation with an appropriate halide. Protective groups which are present are replaced by hydrogen, and finally the acyl radicals in positions 1 and 9 are eliminated, resulting in compounds of the formula XLII. The compounds of the formula XLI are obtained by starting from the compounds which already contain the side chain -CH2-COOR11. The acyl radicals in positions 1 and 9 in these compounds are then eliminated, the 9-hydroxyl group is oxidised to the 9-keto group, and finally the protective group R2 is replaced by hydrogen. The resulting compounds can be used as intermediates for the preparation of prostaglandins.
Acute periprosthetic joint infections (PJI) after dual head arthroplasty represent a major challenge with a 1-year mortality rate up to 50% in the mostly multimorbid geriatric patient collective. Due to the limited possibilities of preoperative patient optimization, infection rates of up to 9% have been reported, which is significantly higher than in elective arthroplasty. A therapeutic gold standard has not yet been established due to the heterogeneous study situation and the lack of prospective randomized studies. The most promising therapeutic option currently appears to be a single-stage stem replacement in combination with implantation of a cup component (conversion to total hip arthroplasty, infection eradication in up to 100%). An approach of débridement, antibiotics, implant retention (DAIR) alone shows significantly poorer success rates (16-82%). Surgical treatment should always be followed by antibiotic treatment with a total duration of 12 weeks. In addition to the established perioperative antibiotic prophylaxis, the use of antibiotic-loaded bone cement seems to be superior to cementless stem fixation in preventing PJI in dual head arthroplasty.
During the first week after randomization, participants will receive 125mg of Epidiolex (CBD) or matching placebo taken twice daily (250mg/day). During the second week after randomization, the dosage will be increased to 250mg of Epidiolex or placebo taken twice daily (500mg/day) for one week. During the third week after randomization, the dosage will be increased to 500mg of Epidiolex (CBD) or matching placebo taken twice daily (1000mg/day). Participants will remain on 1000mg/day of Epidiolex (CBD) or matching placebo for four more weeks, at which point they will be stepped down to 500mg/day of Epidiolex (CBD) or placebo for one week, followed by 250mg/day of Epidiolex (CBD) or placebo for one week.
Mazindol controlled release taken once daily. Dosage starting at 1 mg increasing or decreasing in increments of 1 mg depending on efficacy and tolerability. Maximum dose during the study is 3 mg taken once daily.
Participants received either 75 milligrams per square meter (mg/m\^2) docetaxel by IV infusion over approximately 1 hour or 320 mg/m\^2 vinflunine by IV infusion over approximately 20 minutes or 175 mg/m\^2 paclitaxel by IV infusion over approximately 1 hour on day 1 of every 21-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.
Fasted participants will receive a single oral dose of BIIB061 30 mg. Following a washout period, participants will receive the same dose of BIIB061 after a high-fat, high-calorie meal (fed state).
According to our local protocol, until December 2021, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
Aerobic Exercise (AE) subjects will come in for supervised, aerobic exercise training sessions 5 days a week for 12 weeks. Training will progress from 55% VO2max for week 1 (40 min session), to 60-65% VO2max for week 2 (50 min session), to \~70% VO2max for all other weeks (50 min session). Subjects will perform a warm-up and cool down (\~5 min each) that includes stretching exercises. Subjects will wear heart rate monitors during each training session to provide feedback of target heart rate. Intensity, duration, resting and exercise heart rates, and blood pressures will be recorded for each session. Follow-up VO2max tests will be performed at weeks 4 and 8 to monitor progress and adjust AE training intensity.
Patients receive veliparib PO BID on day 1 and nivolumab IV over 30 minutes on days 1 and 15 of courses 1-4 and IV over 60 minutes on day 1 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Irregular sleep and non-optimal sleep duration separately have been shown to be associated with increased disease and mortality risk. We used data from the prospective cohort Multi-Ethnic Study of Atherosclerosis sleep study (2010-2013) to investigate: do aging adults whose sleep is objectively high in regularity in timing and duration, and of sufficient duration tend to have increased survival compared with those whose sleep is lower in regularity and duration, in a diverse US sample? At baseline, sleep was measured by 7-day wrist actigraphy, concurrent with at-home polysomnography and questionnaires. Objective metrics of sleep regularity and duration from actigraphy were used for statistical clustering using sparse k-means clustering. Two sleep patterns were identified: "regular-optimal" (average duration: 7.0 ± 1.0 hr obtained regularly) and "irregular-insufficient" (duration: 5.8 ± 1.4 hr obtained with twice the irregularity). Using proportional hazard models with multivariate adjustment, we estimated all-cause mortality hazard ratios. Among 1759 participants followed for a median of 7.0 years (Q1-Q3, 6.4-7.4 years), 176 deaths were recorded. The "regular-optimal" group had a 39% lower mortality hazard than did the "irregular-insufficient" sleep group (hazard ratio [95% confidence interval]: 0.61 [0.45, 0.83]) after adjusting for socio-demographics, lifestyle, medical comorbidities and sleep disorders. In conclusion, a "regular-optimal" sleep pattern was significantly associated with a lower hazard of all-cause mortality. The regular-optimal phenotype maps behaviourally to regular bed and wake times, suggesting sleep benefits of adherence to recommended healthy sleep practices, with further potential benefits for longevity.
1. Technical Result Increase in stability of liquid aerosol composition. 2. Essence A liquid composition for use in an aerosol inhaler comprising an active material, a propellant containing a hydrofluoroalkane, a cosolvent and optionally a low volatility component is stabilized by adding a small amount of mineral acid and using a suitable can having part or all of its internal metallic surfaces made of stainless steel, anodized aluminium or lined with an inert organic coating. 3. Field of Application Medicine.
SNX29 is a potential functional gene associated with meat production traits. Previous studies have shown that SNX29 copy number variation (CNV) could be implicated with phenotype in goats. However, in Diannan small-ear (DSE) pigs, the genetic impact of SNX29 CNV on growth traits remains unclear. Therefore, this study investigated the associations between SNX29 CNVs (CNV10810 and CNV10811) and growth traits in 415 DSE pigs. The results revealed that the CNV10810 mutation was significantly associated with backfat thickness in DSE pigs at 12 and 15 months old (P < 0.05), while the CNV10811 mutation had significant effects on various growth traits at 6 and 12 months old, particularly for body weight, body height, back height and backfat thickness (P < 0.05 or P < 0.001). In conclusion, our results confirm that SNX29 CNV plays a role in regulating growth and development in pigs, thus suggesting its potential application for pig breeding programmes.
The invention discloses application of a gene editing system in constructing a cystic fibrosis model pig nuclear transfer donor cell with CFTR gene mutation. The present invention provides SEQ ID NO:16, CFTR-gRNA1, SEQ ID NO:17 and NCN protein in the preparation of a kit. The invention also provides a method for preparing the recombinant pig cell: and co-transfecting the CFTR-gRNA1, the CFTR-gRNA3 and the NCN protein into the pig cells to obtain recombinant pig cells. The recombinant porcine cell is a recombinant porcine cell with a CFTR gene mutation. The kit has the following purposes: preparing recombinant pig cells; preparing a cystic fibrosis model pig; preparing a cystic fibrosis cell model or a cystic fibrosis tissue model or a cystic fibrosis organ model. The invention has great application value for research and development of cystic fibrosis medicines and revealing pathogenesis of the cystic fibrosis.
BACKGROUND: Individuals with inflammatory bowel disease (IBD) exhibit a heightened likelihood of developing erythema nodosum (EN), but the presence of causal link is unknown. The purpose of the present research was to investigate this connection using a bidirectional two-sample Mendelian randomization (MR) analysis.
METHODS: Summarized statistics for EN were sourced from the FinnGen consortium of European ancestry. The International Inflammatory Bowel Disease Genetic Consortium (IBDGC) was used to extract summary data for IBD. The inverse variance weighted (IVW) technique was the major method used to determine the causative link between them.
RESULTS: The study evaluated the reciprocal causal link between IBD and EN. The IVW technique confirmed a positive causal link between IBD and EN (OR = 1.237, 95% CI: 1.109-1.37, p = 1.43 × 10- 8), as well as a strong causality connection between Crohn's disease (CD) and EN (OR = 1.248, 95% CI: 1.156-1.348, p = 1.00 × 10- 4). Nevertheless, a causal connection between ulcerative colitis (UC) and EN could not be established by the data. The reverse MR research findings indicated that analysis indicated that an increase in EN risks decreased the likelihood of UC (OR = 0.927, 95% CI: 0.861-0.997, p = 0.041), but the causal association of EN to IBD and CD could not be established.
CONCLUSION: This investigation confirmed that IBD and CD had a causal connection with EN, whereas UC did not. In addition, EN may decrease the likelihood of UC. Further study must be performed to uncover the underlying pathophysiological mechanisms producing that connection.
The invention relates to a peptide (PINHE) comprising 28 amino acids, which is obtained by fractionation and purification of the supernatant of the culture of Haloferax gibbonsii alicante SPH7. PINHE acts as a natural physiological inhibitor of the Na+/H+ exchanger in eukaryotes. Moreover, PINHE is active in wide ranges of saline concentrations, temperature and pH as well as being trypsin resistant and pronase sensitive.  Owing to the reversible action of said peptide on the Na+/H+ exchanger, it can be used (1) for the treatment or prophylaxis of pathologies such as cardiovascular, renal, cerebral and metabolic diseases, pathological proliferative processes, hyperproduction of hydrochloric acid, etc. and (2) for other diseases or pathologies associated with a post-ischemic reperfusion lesion and ischemia caused by hyperactivity of the NHE, such as ischemias caused by primary or secondary vascular alterations in different tissues, by post-infarction reperfusion, by an organ or tissue transplant, etc.  The inventive peptide can also be used as a contraceptive (in male mammals), an antibiotic or an immunoregulatory agent and in plants as a saline stress modulator.
The present study was a randomized controlled trial that explored the feasibility, acceptability, and effectiveness of short-term mindfulness training among adolescents. The primary purpose was to investigate the effectiveness of two main Mindfulness-Based Stress Reduction components-sitting meditation and hatha yoga-on working memory, stress, anxiety and mindfulness. The influence of daily home practice compliance on intervention outcomes was also examined. Participants (N = 198 adolescents) were recruited from a large public middle school in southern California. Participants were randomly assigned to sitting meditation, hatha yoga, or a waitlist control group. Participants were asked to complete a computerized working memory task, and self-report measures of perceived stress, anxiety, and mindfulness at pre- and post-intervention/waitlist, as well as one-month follow-up. A series of mixed-design analyses of variance (ANOVAs) were used to examine changes in working memory, stress, anxiety, and mindfulness between groups at pre- and post- intervention.
A cosmetic composition for temporarily reshaping keratinous fibres, comprising: a) at least one cationically modified guar derivative with a weight average molecular weight in the range from about 5,000 to about 200,000 and a degree of cationic substitution in the range from about 0.1 to about 2, and b) at least one copolymer comprising (b1) quaternised vinylimidazole and (b2) vinylpyrrolidone as monomers. Preferably, the cationically modified guar derivative is Guar Hydroxypropyltrimonium Chloride. Preferably, the copolymer is Polyquaternium-16. The composition may further comprise an organic acid, or salt thereof (e.g. lactic acid). The composition may also comprise water as at least 20 wt.% of the composition. Also claimed is the use of a cosmetic composition as described for temporarily reshaping keratinous fibres. Further claimed is a method for temporarily reshaping keratin fibres in which a cosmetic composition as described is applied to keratinous fibres.
Primary cutaneous gamma delta T-cell lymphoma (PCGDTCL) is a rare type of non-Hodgkin lymphoma accounting for <1% of primary cutaneous T-cell lymphomas. The exact cause of PCGDTCL is not known, however, it is thought that chronic antigen exposure in the skin may lead to immune dysregulation at the site, resulting in abnormal proliferation of mature, post-thymic cytotoxic gamma delta T cells. Mutations are the most common genetic alteration seen in PCGDTCL, while structural abnormalities such as gene fusions are not common. We report a case of PCGDTCL with atypical immunophenotypic features, including expression of CD5 with lack of cytotoxic marker expression, and a structural alteration leading to FYN deletion at exon 8. Recently, it was described that a deletion of the area between FYN exon 8 and TRAF3IP2 intron 2 results in a novel FYN::TRAF3IP2 fusion in peripheral T-cell lymphoma, not otherwise specified. We describe our patient's clinical course, differential diagnosis, and potential implications of FYN deletion on disease pathogenesis. To our knowledge, this is the first report of an FYN structural alteration to be described in PCGDTCL.
<P>PROBLEM TO BE SOLVED: To solve problems that pyroligneous acid has difficulties in a strong offensive odor and imparts an unpleasant feeling to users in use though a liquid consisting essentially of the pyroligneous acid is placed even on the market as a therapeutic agent for dermatosis caused by trichophytons such as tineas because vinegar is conventionally known to have sterilizing effects.  <P>SOLUTION: Special water is produced by subjecting water containing mineral metal ions having a great ionizing tendency to a treatment of an electric field and/or a magnetic field. Ferrous ions (Fe<SP>2+</SP>) are preferably used as the mineral metal ions having the great ionizing tendency and the ion concentration is preferably adjusted to 40-45 ppm. The special water has no taste and odor without imparting the unpleasant feeling to the users. When the special water is applied to affected parts, the trichophytons are damaged to effectively cure the dermatosis such as athlete's foot caused by the trichophytons.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
BACKGROUND: Medical emergency teams (METs) are in place in some hospitals in Finland to respond to critical emergency events. However, in hospitals without dedicated METs, staff are instructed to call emergency medical services (EMS) to deal with emergencies. This study examined the reasons for calling EMS to hospitals and the outcomes of these calls.
METHODS: Descriptive retrospective register-based study of the response and management of in-hospital emergencies by EMS in the wellbeing services county of Southwest Finland. Patient care reports of the EMS and those of the hospitals were analysed.
RESULTS: In total, 138 medical emergencies managed by EMS were included in this study. 108 of these related to patients, and 25 related to hospital personnel. Cardiac arrest (n = 36) and a reduced level of consciousness (n = 29) were the most common in-hospital emergencies. In 68% of in-hospital emergencies managed by the EMS team, after calling 112, hospital personnel implemented various treatment measures. In 72% of cases, follow-up treatment was required.
CONCLUSIONS: Hospital personnel are able to initiate medical measures in emergencies, even when no MET is available. Although EMS are important in responding to in-hospital emergencies, they seem to be performing the same role as METs.
Patients will receive a 4 cmH2O continuous positive airway pressure device during 4 nights; this is the minimum pressure necessary to avoid death space with no effect on minute ventilation. The equipment will be placed ad libitum. Pressure will be administered through a nasal mask. CRP, FEV1, exhaled fraction of nitric oxide, IL-4, IL-5, IL-13, IL-17, IgE, cell count will be measured before and after sham intervention.
Study 109609 is a single-arm, non-randomized, single-stage Phase II study of pazopanib in subjects with Stage IIIB or IV non-small cell lung cancer who have progressed after one or two prior regimens of systemic therapy. The study will be conducted at a limited number of institutions in the US. A total of 40 evaluable subjects will be enrolled and treated. Pazopanib will be given at a dose of 800mg (as determined by previous Phase I studies) orally once per day. Subjects may continue to receive study drug for up to two years unless they experience disease progression or withdraw from treatment for other reasons, or unless the Sponsor terminates the study. A rollover study may be available to those subjects who are exhibiting clinical benefit (stable disease or better). Evaluable subjects will be assessed for response as the primary endpoint.